-
Measurement of fetal nuchal translucency thickness by three-dimensional ultrasound.
Paul C, Krampl E, Skentou C, Jurkovic D, Nicolaides KH.
Ultrasound Obstet Gynecol 2001;18:481-4. -
Osteogenesis imperfecta and other skeletal dysplasias presenting with increased nuchal translucency in the first trimester.
Makrydimas G, Souka A, Skentou H, Lolis D, Nicolaides K.
Am J Med Genet 2001;98:117-20. -
First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction.
Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH.
Hum Reprod 2001;16:1501-4. -
Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype.
Ghi T, Huggon IC, Zosmer N, Nicolaides KH.
Ultrasound Obstet Gynecol 2001;18:610-4. -
Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study.
Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides K.
Lancet 2001;358:1665-7. -
First trimester markers of trisomy 21 and the influence of maternal cigarette smoking status.
Spencer K, Ong CYT, Liao AWJ, Papademetriou D, Nicolaides KH.
Prenat Diagn 2000;20:852-3. -
The influence of parity and gravidity on first trimester markers of chromosomal abnormality.
Spencer K, Ong CYT, Liao AWJ, Papademetriou D, Nicolaides KH.
Prenat Diagn 2000;20:792-4. -
First trimester prenatal diagnosis of trisomy 21 in discordant twins using fetal nuchal translucency thickness and maternal serum free beta-hCG and PAPP-A.
Spencer K, Nicolaides KH.
Prenat Diagn 2000;20:683-4. -
The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K, Ong CY, Liao AW, Papademetriou D, Nicolaides KH.
Prenat Diagn 2000;20:673-5. -
Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K, Liao AW, Skentou H, Cicero S, Nicolaides KH.
Prenat Diagn 2000;20:495-9. -
Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K, Ong C, Skentou H, Liao AW, Nicolaides KH.
Prenat Diagn 2000;20:411-6. -
One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester.
Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH.
BJOG 2000;107:1271-5. -
Early prediction of severe twin-to-twin transfusion syndrome.
Sebire NJ, Souka A, Skentou H, Geerts L, Nicolaides KH.
Hum Reprod 2000;15:2008-10. -
The 11-14 week scan.
Nicolaides KH, Heath V, Liao AW.
Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:581-94. -
Increased fetal nuchal translucency: possible association with esophageal atresia.
Brown RN, Nicolaides KH.
Ultrasound Obstet Gynecol 2000;15:531-2. -
Hyaluronan in the nuchal skin of chromosomally abnormal fetuses.
Bohlandt S, von Kaisenberg CS, Wewetzer K, Christ B, Nicolaides KH, Brand-Saberi B.
Hum Reprod 2000;15:1155-8. -
Pathophysiology of increased nuchal translucency in chromosomally abnormal fetuses.
von Kaisenberg CS, Brand-Saberi B, Jonat W, Nicolaides KH.
Der Gynäkologe 1999;32:193-199. -
Lymphatic vessel hypoplasia in fetuses with Turner syndrome.
von Kaisenberg CS, Nicolaides KH, Brand-Saberi B.
Hum Reprod 1999;14:823-6. -
Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta -hCG and PAPP-A at 10-14 weeks of gestation.
Tul N, Spencer K, Noble P, Chan C, Nicolaides K.
Prenat Diagn 1999;19:1035-42. -
A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;13:231-7.